Update: Viavi Fiscal Q3 Non-GAAP Earnings, Revenue Surge; Q4 Outlook Beats; Shares Soar Premarket

-- (Updates with the stock move in the headline and the first paragraph)

Viavi Solutions (VIAV) shares rose 23% in Thursday's premarket activity after the firm overnight reported a stronger-than-expected surge in fiscal Q3 earnings and sales, and its guidance for the next quarter was also above consensus.

The company reported fiscal Q3 non-GAAP earnings late Wednesday of $0.27 per diluted share, up from $0.15 a year earlier.

Analysts surveyed by FactSet expected $0.23.

Net revenue for the quarter ended March 28 was $406.8 million, compared with $284.8 million a year earlier.

Analysts polled by FactSet expected $393.8 million.

The firm said it expects fiscal Q4 non-GAAP EPS of $0.29 to $0.31 on net revenue of $427 million to $437 million.

Analysts expect $0.24 and $402.2 million, respectively.

Price: $56.00, Change: $+10.47, Percent Change: +23.00%

法国巴黎银行将英格索兰的目标股价从94美元下调至82美元。

根据FactSet调查的分析师报告，英格索兰(IR)的平均评级为“增持”，平均目标价为96.80美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $77.89, Change: $+0.43, Percent Change: +0.56%

$IR

瑞穗证券将Humana的目标股价从258美元上调至290美元。

根据FactSet调查的分析师数据，Humana (HUM) 的平均评级为“持有”，平均目标价为228.67美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $242.12, Change: $-1.00, Percent Change: -0.41%

$HUM

杰富瑞将Humana的目标股价从235美元上调至290美元。

$HUM

相关文章

法国巴黎银行将英格索兰的目标股价从94美元下调至82美元。

瑞穗证券将Humana的目标股价从258美元上调至290美元。

杰富瑞将Humana的目标股价从235美元上调至290美元。